Phathom Pharmaceuticals (PHAT) Operating Expenses (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Operating Expenses data on file, last reported at $61.8 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $61.8 million, down 40.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $270.6 million (down 24.19% YoY), and the FY2025 annual result was $312.5 million, down 3.77% from the prior year.
• Operating Expenses rose to $61.8 million in Q1 2026 per PHAT's latest filing, from $55.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $103.7 million in Q1 2025 and troughed at $30.1 million in Q1 2023.
• A 5-year average of $61.1 million and a median of $58.6 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2026: Operating Expenses soared 162.6% in 2024, then slumped 40.4% in 2026.
• A 5-year view of Operating Expenses shows it stood at $46.6 million in 2022, then jumped by 50.92% to $70.4 million in 2023, then grew by 21.13% to $85.3 million in 2024, then slumped by 34.48% to $55.9 million in 2025, then grew by 10.59% to $61.8 million in 2026.
• Business Quant data shows PHAT's Operating Expenses at $61.8 million in Q1 2026, $55.9 million in Q4 2025, and $58.6 million in Q3 2025.